FDA works with US health insurers to identify drug problemsBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39559.404560.DB (Published 24 April 2008) Cite this as: BMJ 2008;336:913
- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration is joining with health insurance companies to try to identify adverse drug events faster.
At present the FDA relies on voluntary reporting of problems by doctors, drug companies, and the public.
Doctors and patients have been calling for a better reporting system after well publicised problems with some drugs, such as rofecoxib (Vioxx), which was withdrawn in September 2004 (BMJ 2004;329:816; doi: 10.1136/bmj.329.7470.816-a); rosiglitazone (Avandia); and antidepressants in children and teenagers.
Health insurance companies, such …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial